Stock listing

NASDAQ:CCCC C4 Therapeutics, Inc. Stock

Home listing (NASDAQ) of C4 Therapeutics, Inc.

Follow C4 Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CCCC

$2.48 USD +0.00 (+0.2%)

Close on Nov 20, 2026

Past year +4.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.32 – $2.55 USDNov 20, 2026
Volume
3.63M sharesNov 20, 2026
Market cap
$325.7M USDAt the close on Nov 20, 2026 · price × 131.3M shares outstanding
52-week range
$1.69 – $5.17 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$7.92M USDMedian day 2.32M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
C4 Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CCCC · Home$2.48 USD+0.005 (+0.2%)3,628,833$2.39$2.545$2.321$2.475Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CCCC · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.48+0.005+0.2%$2.39$2.545$2.3213,628,833
$2.475-0.055-2.2%$2.51$2.605$2.472,749,817
$2.53-0.12-4.5%$2.66$2.66$2.382,839,069
$2.65-0.11-4.0%$2.72$2.76$2.593,105,695
$2.76-0.01-0.4%$2.76$2.85$2.6712,543,577
$2.77-0.12-4.2%$2.86$2.86$2.644,965,262
$2.89-0.11-3.7%$3.04$3.05$2.862,132,635
$3.00-0.15-4.8%$3.11$3.155$2.931,453,554
$3.15+0.05+1.6%$3.13$3.225$3.042,388,734
$3.10+0.15+5.1%$2.96$3.20$2.9512,965,794
$2.95-0.17-5.4%$3.08$3.22$2.9053,683,946
$3.12-0.09-2.8%$3.36$3.385$3.021,971,831
$3.210.000.0%$3.27$3.42$3.171,584,944
$3.21-0.16-4.7%$3.36$3.41$3.162,861,726
$3.37+0.07+2.1%$3.23$3.38$3.212,354,062
$3.30-0.095-2.8%$3.41$3.44$3.202,714,989
$3.395+0.185+5.8%$3.25$3.525$3.234,108,477
$3.21+0.23+7.7%$2.99$3.24$2.954,118,932
$2.98-0.08-2.6%$3.07$3.07$2.943,179,037
$3.06-0.12-3.8%$3.16$3.17$3.024,741,850
$3.18+0.01+0.3%$3.13$3.25$3.121,692,802
$3.17+0.01+0.3%$3.15$3.22$3.102,189,796
$3.16+0.27+9.3%$2.86$3.20$2.8553,689,396
$2.89+0.125+4.5%$2.80$2.94$2.803,113,184
$2.765-0.015-0.5%$2.78$2.81$2.6952,359,300
$2.78+0.17+6.5%$2.64$2.846$2.603,274,900
$2.61-0.17-6.1%$2.72$2.795$2.593,094,000
$2.78-0.28-9.2%$3.04$3.06$2.753,821,400
$3.06-0.10-3.2%$3.16$3.30$3.051,500,400
$3.16+0.31+10.9%$3.00$3.19$2.952,506,100
$2.85+0.03+1.1%$2.80$2.88$2.7212,827,700
$2.82-0.06-2.1%$2.85$2.95$2.822,267,500
$2.88-0.11-3.7%$3.02$3.03$2.792,113,100
$2.99+0.04+1.4%$3.01$3.10$2.951,463,600
$2.95-0.19-6.1%$3.19$3.33$2.933,384,900
$3.14-0.19-5.7%$3.31$3.37$3.1351,891,600
$3.33+0.20+6.4%$3.16$3.37$3.132,609,200
$3.13+0.015+0.5%$3.09$3.215$3.001,554,100
$3.115+0.135+4.5%$3.015$3.16$2.982,776,000
$2.98-0.05-1.7%$3.03$3.115$2.9252,116,800
$3.03-0.05-1.6%$3.03$3.06$2.882,807,600
$3.08-0.23-6.9%$3.32$3.34$2.9254,592,400
$3.31+0.01+0.3%$3.33$3.42$3.2851,357,800
$3.30-0.09-2.7%$3.44$3.45$3.2452,050,500
$3.39-0.025-0.7%$3.43$3.475$3.381,630,900
$3.415-0.035-1.0%$3.51$3.59$3.401,758,200
$3.45+0.02+0.6%$3.44$3.53$3.4252,320,800
$3.430.000.0%$3.40$3.455$3.321,344,100
$3.43-0.08-2.3%$3.46$3.54$3.411,485,400
$3.51+0.11+3.2%$3.475$3.525$3.3551,472,300
$3.40-0.04-1.2%$3.40$3.41$3.311,167,600
$3.44-0.11-3.1%$3.54$3.54$3.421,441,300
$3.55-0.21-5.6%$3.72$3.735$3.552,172,400
$3.76+0.02+0.5%$3.72$3.845$3.662,363,400
$3.74-0.05-1.3%$3.83$3.85$3.702,227,700
$3.79-0.08-2.1%$3.87$4.07$3.731,835,400
$3.87+0.16+4.3%$3.68$3.935$3.662,364,100
$3.71-0.14-3.6%$3.83$3.86$3.6951,857,200
$3.85-0.25-6.1%$4.07$4.10$3.831,824,700
$4.10-0.14-3.3%$4.25$4.30$4.091,988,400
$4.24+0.04+1.0%$4.17$4.24$4.031,861,700
$4.20+0.10+2.4%$4.11$4.235$4.0854,285,800
$4.10+0.10+2.5%$3.97$4.14$3.811,752,900
$4.00-0.03-0.7%$4.07$4.10$3.9351,160,600
$4.03-0.18-4.3%$4.14$4.15$3.8322,272,700
Ticker
NASDAQ:CCCC
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All C4 Therapeutics, Inc. news

C4 Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 116 in all · newest Nov 5, 2026 · oldest 2020
Decks
37 decks · latest Sep 25, 2026

Where C4 Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CCCC · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CCCCBOATSUnited StatesUSD

Valuation

EV/sales 5.4× against a median of 2,281×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$175.5M USD
P/E
Loss
EV/sales
5.4×
EV/EBITDA
Negative EBITDA
Price/book
1.4×
Gross margin
94.4%
Operating margin
−315.9%
Net margin
−282.2%
Debt to equity
0.2×
Beta vs S&P 500
1.46

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
C4 Therapeutics, Inc. · NASDAQ:CCCCUS$325.7MUS$175.5Mn/a5.4×n/a1.4×−282.2%0.2×1.46
Lyell Immunopharma, Inc. · NASDAQ:LYELUS$339.3MUS$196.5Mn/a13,099×n/a1.8×n/a0.2×1.51
Avacta Group PLC · LSE:AVCTUS$337.8MUS$337.2Mn/a2,281×n/a68.5×n/a5.3×n/a
Inovio Pharmaceuticals, Inc. · NASDAQ:INOUS$329.7MUS$7.56Bn/a25,303×3.4×n/an/an/a0.70
Larimar Therapeutics, Inc. · NASDAQ:LRMRUS$328.6MUS$204.7Mn/an/an/a3.2×n/a0.1×1.48
CytoDyn Inc. · OTC:CYDYUS$326.4MUS$345.8Mn/an/an/an/an/an/a0.44
Laekna, Inc. · HKEX:2105US$322.8MUS$154.7Mn/a9.7×n/a1.8×−214.9%0.0×n/a
Foresee Pharmaceuticals Co., Ltd. · TPEX:6576US$319.8MUS$303.4M469×21.2×n/a8.3×4.8%0.3×n/a
GI Innovation, Inc. · KRX:358570US$317.8MUS$288.6Mn/an/an/a4.4×n/a0.0×n/a
Atea Pharmaceuticals, Inc. · NASDAQ:AVIRUS$317.6MUS$126.6Mn/an/an/a1.8×n/a0.0×0.86
MapLight Therapeutics, Inc. · NASDAQ:MPLTUS$313.9MUS$29.84Mn/an/an/a0.7×n/a0.0×1.28
Median of the othersUS$324.6MUS$246.6M469×2,281×3.4×2.5×−105.1%0.0×1.07

Forecasts

7 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
12.50 USD · Analysts' mean
EPS, year to Dec 2026
-0.75 · 6 analysts
Revenue, year to Dec 2026
26.85M · 6 analysts

Team and board

Officers

OfficerRole
Andrew HirschPresident and Chief Executive Officer, Director
Courtney SolbergAssociateDirector, Investor Relations
Leah GibsonVice President, Investor Relations & Communications
Marc CohenIn MemoriamCo-Founder & Executive Chairman Emeritus

Board

DirectorRole
Marc CohenIn MemoriamCo-Founder & Executive Chairman Emeritus
Ron CooperChairman
Andrew HirschPresident and Chief Executive Officer, Director
Donna GroganDirector
Ken AndersonDirector
Laura BessenDirector
Owen HughesDirector
Stephen FawellDirector
Steve HoerterDirector
Utpal KoppikarDirector

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−5.5%
Q2 2026Aug 11, 2026 · Before open+6.9%
Q1 2026May 12, 2026 · Before open0.0%
Q4 2025Feb 26, 2026−2.5%
Q3 2025Nov 6, 2025 · Before open+0.4%
Q2 2025Aug 7, 2025 · Before open+31.6%
Q1 2025May 7, 2025 · Before open+6.4%
Q4 2024Feb 20, 2025 · Before open−0.7%
Q3 2024Oct 31, 2024 · Before open−3.6%
Q2 2024Aug 1, 2024 · Before open−0.3%
All 20 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · Before open−5.0%
Q4 2023Feb 22, 2024 · Before open+21.4%
Q3 2023Nov 1, 2023 · Before open−11.4%
Q2 2023Aug 8, 2023 · Before open−0.3%
Q1 2023May 4, 2023 · Before open+2.9%
Q4 2022Feb 23, 2023 · Before open+1.7%
Q3 2022Nov 3, 2022 · Before open+2.1%
Q2 2022Aug 4, 2022 · Before open+7.0%
Q1 2022May 5, 2022 · Before open−4.0%
Q4 2021Feb 24, 2022 · Before open+14.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck25 slidesSep 25, 2026
Investor Presentation (June 2026)Investor deck26 slidesJun 11, 2026
Investor Presentation (May 2026)Investor deck23 slidesMay 12, 2026
Investor Presentation (April 2026)Investor deck26 slidesApr 9, 2026
Investor Presentation (October 2025)Investor deck33 slidesOct 16, 2025
International Myeloma Society (IMS) Annual Meeting 2025Conference39 slidesSep 22, 2025
Corporate Update (August 2025)Corporate update23 slidesAug 7, 2025
Investor Presentation (May 2025)Investor deck26 slidesMay 2025
Investor Presentation (January 2025)Investor deck37 slidesJan 14, 2025
Investor Presentation (December 2024)Investor deck37 slidesDec 9, 2024
All 37 decks
DeckKindSlidesDate
American Society of Hematology (ASH) Annual Meeting 2024Conference35 slidesDec 9, 2024
Investor Presentation (October 2024)Investor deck29 slidesOctober 2024
Investor Presentation (October 2024)Investor deck30 slidesOctober 2024
ESMO Congress 2024Conference15 slidesSep 13, 2024
Investor Presentation (September 2024)Investor deck29 slidesSeptember 2024
Investor Presentation (May 2024)Investor deck30 slidesMay 2024
Investor Presentation (March 2024)Investor deck30 slidesMarch 2024
Investor Presentation (February 2024)Investor deck30 slidesFebruary 2024
Investor Presentation (January 2024)Investor deck31 slidesJanuary 2024
Technical Presentation (December 2023)Technical39 slidesDec 12, 2023
Investor Presentation (November 2023)Investor deck24 slidesNovember 2023
Investor Presentation (October 2023)Investor deck26 slidesOctober 2023
Investor Presentation (August 2023)Investor deck26 slidesAugust 2023
Investor Presentation (July 2023)Investor deck29 slidesJuly 2023
Investor Presentation (January 2023)Investor deck29 slidesJan 9, 2023
Technical Presentation (2023)Technical16 slides2023
Technical Presentation (April 2022)Technical25 slidesApr 8, 2022
4th Annual TPD (Targeted Protein Degradation) Summit (October 2021)Conference16 slidesOct 27, 2021
4th Targeted Protein Degradation Summit 2021Conference29 slidesOctober 2021
Technical Presentation (June 2021)Technical19 slidesJun 7, 2021
Investor Presentation (May 2021)Investor deck42 slidesMay 26, 2021
Undruggable Leaders Forum Europe 2021Conference23 slidesApr 13, 2021
AACR Annual Meeting 2021Conference13 slidesApril 2021
Investor Presentation (January 2021)Investor deck36 slidesJan 12, 2021
World Pharma Week 2020Conference22 slidesDec 10, 2020
Investor Presentation (November 2020)Investor deck23 slidesNov 19, 2020
Targeted Protein Degradation Summit 2020Conference25 slidesOct 14, 2020

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants, each with a Class A Warrant and a Class B Warrant
Announced: US$125M–US$349.7M · US$2.47 a share · Warrants at US$2.22 · Jefferies +2
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead)
Buyers: RA Capital Management (led the offering); OrbiMed; Soleus Capital; Lynx1 Capital Management; Bain Capital Life Sciences
Use of proceeds: Fund ongoing and planned clinical trials of cemsidomide, other R&D, working capital and general corporate purposes
Oct 16, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$19.00 a share on Oct 1, 2020.

Price
US$19.00 a share
Shares offered
9,600,000 shares of common stock
Offering size
US$182.4 million
Underwriters' option
Up to 1,440,000 more shares
Underwriters
Jefferies, Evercore ISI, BMO Capital Markets, UBS Investment Bank · In the order on the cover
Shares delivered
On or about Oct 6, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceAug 6, 2020
Filed publiclySep 10, 2020
Amended onceSep 28, 2020
Shares registered with an exchangeSep 28, 2020
Declared effective by the SECOct 1, 2020
Final prospectus, with the priceOct 2, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Oct 2, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue35.9M35.6M20.8M31.1M45.8M33.2M21.4M19.4M
Cost of revenue7.97M7.89M7.74M7.57M2.91M78.4M47.7M28.6M
Gross profit28.0M35.6M13.0M31.1M45.8M-45.2M21.4M-9.23M
Research and development104.2M110.6M117.7M117.8M94.7M78.4M48.1M28.6M
Selling, general and administrative36.2M42.1M42.1M42.8M33.3M15.2M8.77M7.16M
Operating income-115.2M-119.6M-139.0M-129.5M-82.1M-60.4M-35.5M-16.4M
Depreciation and amortization1.96M1.82M1.88M1.68M1.49M1.62M1.59M1.27M
EBITDA-113.3M-117.8M-137.2M-127.9M-80.6M-58.8M-33.9M-15.1M
Interest expense01.37M2.22M2.15M1.23M2.16M0
Income before tax-104.9M-105.2M-131.2M-128.2M-83.9M-67.0M-33.3M-15.7M
Income tax121.0K131.0K1.28M00-626.0K804.0K678.0K
Net income-105.0M-105.3M-132.5M-128.2M-83.9M-66.3M-34.1M-15.7M
Earnings per share, basic-1.27-1.52-2.67-2.62-1.82-5.83-31.03-0.37
Earnings per share, diluted-1.27-1.52-2.67-2.62-1.82-5.83-31.03

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents74.6M55.5M126.6M29.8M76.1M181.7M90.5M36.3M
Short-term investments173.9M189.4M127.1M246.4M233.2M190.0M
Receivables2.40M3.10M11.8M1.47M5.72M4.48M4.62M86.4M
Inventory-61.0M11
Current assets258.1M257.8M271.2M287.6M325.7M381.0M96.8M123.5M
Property, plant and equipment4.74M5.84M7.13M7.40M3.11M3.32M4.46M20.4M
Total assets359.1M349.6M376.5M430.8M506.8M400.1M118.3M146.5M
Accounts payable858.0K1.33M1.45M1.17M4.51M5.68M5.38M1.15M
Current liabilities33.0M45.2M42.8M44.5M51.2M43.9M33.6M23.9M
Long-term debt09.20M10.8M10.1M
Total debt60.0M65.8M011.5M10.8M10.1M13.7M14.5M
Total liabilities102.5M133.6M130.3M141.6M117.2M119.3M119.2M226.2M
Shareholders' equity256.6M216.0M246.1M289.2M389.6M280.8M-112.0M-79.8M
Shares outstanding96.9M70.6M60.5M49.0M48.7M43.1M1.43M42.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-98.7M-65.2M-106.8M-105.9M-87.0M-67.2M55.6M-17.0M
Capital spending-607.0K-180.0K-1.71M-5.50M-1.28M-650.0K-1.35M-2.69M
Free cash flow-99.3M-65.3M-108.5M-111.4M-88.2M-67.9M54.3M-19.7M
Cash from investing-8.60M-51.3M158.3M58.4M-189.3M-190.5M-1.62M36.9M
Cash from financing126.4M45.3M45.5M1.15M171.4M348.9M244.0K1.96M
Dividends paid-12.0M
Share buybacks-193.0K-194.0K-110.0K02.04M-194.0K-30.0K-63.0K
Change in cash19.1M-71.1M97.0M-46.4M-104.9M91.2M54.2M21.9M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
8-K · Current reportSep 25, 2026Current reportSEC
4 · Change in ownershipSep 21, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
144 · Notice of proposed saleAug 14, 2026Other filingsSEC
144 · Notice of proposed saleAug 14, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 13, 2026Other filingsSEC
144 · Notice of proposed saleAug 12, 2026Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 11, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
4 · Change in ownershipJul 13, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
4 · Change in ownershipJun 26, 2026Insider tradeSEC
8-K · Current reportJun 24, 2026Meeting outcomeSEC
8-K · Current reportJun 11, 2026Current reportSEC
4 · Change in ownershipJun 4, 2026Insider tradeSEC
144 · Notice of proposed saleMay 28, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeMay 19, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
8-K · Current reportMay 15, 2026Management or board changeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
8-K · Current reportMay 12, 2026ResultsSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 22, 2026Big-stake noticeSEC
8-K · Current reportApr 10, 2026Current reportSEC
8-K · Current reportApr 9, 2026Material contractSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
144 · Notice of proposed saleMar 9, 2026Other filingsSEC
S-8 · Registration statement for employee plansFeb 26, 2026Offer documentSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2026Big-stake noticeSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
8-K · Current reportJan 14, 2026Current reportSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveDec 11, 2025Other filingsSEC
424B5 · ProspectusDec 10, 2025Offer documentSEC
CORRESP · Letter to the SECDec 8, 2025Other filingsSEC
S-3 · Registration statementNov 21, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 24, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 24, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 20, 2025Big-stake noticeSEC
8-K · Current reportOct 16, 2025Material contractSEC
424B5 · ProspectusOct 16, 2025Offer documentSEC
FWP · Free writing prospectusOct 16, 2025Offer documentSEC
8-K · Current reportOct 16, 2025Current reportSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
8-K · Current reportOct 1, 2025Current reportSEC
8-K · Current reportSep 22, 2025Current reportSEC
4 · Change in ownershipSep 19, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 7, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
4/A · Change in ownership, amendedJul 15, 2025Insider tradeSEC
4 · Change in ownershipJul 14, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJul 2, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
8-K · Current reportJun 18, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 7, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 7, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025ResultsSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 16, 2025Meeting noticeSEC
8-K · Current reportApr 14, 2025Management or board changeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
S-8 · Registration statement for employee plansFeb 27, 2025Offer documentSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 3, 2025Big-stake noticeSEC
8-K · Current reportJan 14, 2025ResultsSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
4 · Change in ownershipJan 3, 2025Insider tradeSEC
8-K · Current reportDec 9, 2024Current reportSEC
4 · Change in ownershipNov 21, 2024Insider tradeSEC
3 · Initial statement of ownershipNov 21, 2024Insider tradeSEC
8-K · Current reportNov 20, 2024Management or board changeSEC
144 · Notice of proposed saleNov 18, 2024Other filingsSEC
424B3 · ProspectusNov 15, 2024Offer documentSEC
424B5 · ProspectusNov 15, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveNov 14, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveNov 14, 2024Other filingsSEC
SUPPLNov 13, 2024Other filingsSEC
SUPPLNov 13, 2024Other filingsSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
CORRESP · Letter to the SECNov 8, 2024Other filingsSEC
CORRESP · Letter to the SECNov 8, 2024Other filingsSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
UPLOAD · Letter from the SECNov 7, 2024Other filingsSEC
UPLOAD · Letter from the SECNov 7, 2024Other filingsSEC
S-3 · Registration statementOct 31, 2024Offer documentSEC
S-3 · Registration statementOct 31, 2024Offer documentSEC
10-Q · Quarterly reportOct 31, 2024Quarterly reportSEC
8-K · Current reportOct 31, 2024ResultsSEC
4 · Change in ownershipOct 29, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 29, 2024Insider tradeSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
144 · Notice of proposed saleOct 18, 2024Other filingsSEC
8-K/A · Current report, amendedOct 15, 2024Management or board changeSEC
8-K · Current reportOct 15, 2024Management or board changeSEC
144 · Notice of proposed saleOct 11, 2024Other filingsSEC
8-K · Current reportOct 11, 2024Management or board changeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipOct 2, 2024Insider tradeSEC
4 · Change in ownershipSep 20, 2024Insider tradeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 17, 2024Insider tradeSEC
4 · Change in ownershipSep 3, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 3, 2024Insider tradeSEC
8-K · Current reportSep 3, 2024Management or board changeSEC
10-Q · Quarterly reportAug 1, 2024Quarterly reportSEC
8-K · Current reportAug 1, 2024ResultsSEC
4 · Change in ownershipJul 11, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJul 10, 2024Big-stake noticeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJul 2, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
8-K · Current reportJun 21, 2024Meeting outcomeSEC
4 · Change in ownershipJun 21, 2024Insider tradeSEC
4 · Change in ownershipJun 11, 2024Insider tradeSEC

This page holds 200 of 552 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from C4 Therapeutics, Inc.’s releases · as of Oct 30, 2026

Common shares
131,317,488
Fully diluted
131,317,488

Fully diluted

LineSharesAs of
Common shares131,317,488Oct 30, 2026

Share count over time

CountShares
Oct 30, 2026131,317,488

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Squadron Capital Management LLC9.32MUS$31MSep 30, 2026
Morgan Stanley8.87MUS$29.5MSep 30, 2026
Ra Capital Management, L.P.8.19MUS$27.3MSep 30, 2026
BlackRock8.18MUS$27.2MSep 30, 2026
Lynx1 Capital Management LP7.53MUS$25.1MSep 30, 2026
Bain Capital Life Sciences Investors, LLC7.17MUS$23.9MSep 30, 2026
Vanguard6.46MUS$21.5MSep 30, 2026
Citadel5.01MUS$16.7MSep 30, 2026
JPMorgan4.7MUS$14.7MSep 30, 2026
Goldman Sachs4.68MUS$15.6MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Wasatch Advisors LP4.16MUS$13.9MSep 30, 2026
Boxer Capital Management, LLC4.15MUS$13.8MSep 30, 2026
Two Sigma3.75MUS$12.5MSep 30, 2026
Silverarc Capital Management, LLC3.45MUS$11.5MSep 30, 2026
Soleus Capital Management, L.P.3.36MUS$11.2MSep 30, 2026
Stempoint Capital LP3.29MUS$11MSep 30, 2026
Bank of America2.89MUS$9.63MSep 30, 2026
Candriam S.C.A.2.76MUS$9.23MSep 30, 2026
Geode Capital2.7MUS$8.99MSep 30, 2026
Qube Research & Technologies Ltd2.4MUS$7.98MSep 30, 2026
ADAR1 Capital Management, LLC2.23MUS$7.44MSep 30, 2026
State Street2.22MUS$7.39MSep 30, 2026
D. E. Shaw & Co., Inc.2.16MUS$7.2MSep 30, 2026
Ikarian Capital, LLC1.93MUS$6.44MSep 30, 2026
Acadian Asset Management LLC1.79MUS$5.95MSep 30, 2026
Dimensional1.38MUS$4.61MSep 30, 2026
Congress Asset Management Co1.26MUS$4.18MSep 30, 2026
Schwab1.23MUS$4.11MSep 30, 2026
Renaissance Technologies1.21MUS$4.03MSep 30, 2026
Fidelity1.18MUS$3.92MSep 30, 2026
Northern Trust1.16MUS$3.85MSep 30, 2026
Atom Investors LP912KUS$3.04MSep 30, 2026
Susquehanna903KUS$3.01MSep 30, 2026
HighVista Strategies LLC873KUS$2.91MSep 30, 2026
Marshall Wace, LLP856KUS$2.85MSep 30, 2026
AQR Capital Management LLC768KUS$2.56MSep 30, 2026
Panagora Asset Management Inc691KUS$2.3MSep 30, 2026
Nuveen592KUS$1.97MSep 30, 2026
Boothbay Fund Management, LLC585KUS$1.95MSep 30, 2026
Platinum Investment Management LTD578KUS$1.92MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.546KUS$1.82MSep 30, 2026
Rockefeller Capital Management L.P.518KUS$1.72MSep 30, 2026
Squarepoint Ops LLC517KUS$1.72MSep 30, 2026
Schroders452KUS$1.41MSep 30, 2026
Wells Fargo396KUS$1.32MSep 30, 2026
Wellington368KUS$1.23MSep 30, 2026
Point72 Asset Management, L.P.340KUS$1.13MSep 30, 2026
Verition Fund Management LLC339KUS$1.13MSep 30, 2026
Rhumbline Advisers339KUS$1.13MSep 30, 2026
Walleye Capital LLC335KUS$1.12MSep 30, 2026

This page holds 50 of 146 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund3.26MUS$15.2MJun 30, 2026
iShares Russell 2000 ETF2.6MUS$12.1MJun 30, 2026
Wasatch Ultra Growth Fund2.5MUS$11.7MJun 30, 2026
Fidelity Small Cap Index Fund1.11MUS$3.86MJul 31, 2026
Vanguard Extended Market Index Fund1.05MUS$4.89MJun 30, 2026
iShares Russell 2000 Value ETF932KUS$4.35MJun 30, 2026
Fidelity Enhanced Small Cap Core ETF781KUS$3.65MJun 30, 2026
Wasatch Micro Cap Fund762KUS$3.56MJun 30, 2026
iShares Biotechnology ETF707KUS$3.3MJun 30, 2026
JNL Multi-Manager Small Cap Value Fund634KUS$2.96MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Fidelity Extended Market Index Fund416KUS$1.82MMay 31, 2026
Schwab U.S. Small-Cap ETF377KUS$1.65MMay 31, 2026
iShares Micro-Cap ETF341KUS$1.59MJun 30, 2026
Small Cap Value Fund307KUS$1.43MJun 30, 2026
Schwab Small-Cap Index Fund246KUS$857KJul 31, 2026
Dimensional U.S. Small Cap ETF235KUS$819KJul 31, 2026
College Retirement Equities Fund - Total Global Stock Account229KUS$1.07MJun 30, 2026
Schwab Small-Cap Equity Fund215KUS$749KJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF207KUS$720KJul 31, 2026
U.S. Micro Cap Portfolio203KUS$706KJul 31, 2026
Master Small Cap Index Series189KUS$885KJun 30, 2026
Wasatch Long/Short Alpha Fund183KUS$853KJun 30, 2026
U.S. Small Cap Portfolio156KUS$541KJul 31, 2026
Fidelity Total Market Index Fund154KUS$675KMay 31, 2026
Fidelity Small Cap Value Index Fund142KUS$662KJun 30, 2026
Nuveen Small Cap Blend Index Fund135KUS$469KJul 31, 2026
Ultra-Small Company Market Fund120KUS$560KJun 30, 2026
Fidelity Series Total Market Index Fund120KUS$523KMay 31, 2026
Dimensional U.S. Core Equity 2 ETF115KUS$401KJul 31, 2026
Avantis U.S. Small Cap Equity ETF115KUS$503KMay 31, 2026
EQ/2000 Managed Volatility Portfolio110KUS$512KJun 30, 2026
VIP Disciplined Small Cap Portfolio92,760US$433KJun 30, 2026
Goldman Sachs Small Cap Equity Insights Fund90,913US$316KJul 31, 2026
Nuveen Equity Index Fund89,883US$313KJul 31, 2026
Goldman Sachs Small Cap Value Insights Fund74,408US$259KJul 31, 2026
LVIP State Street Small-Cap Index Fund73,300US$342KJun 30, 2026
T. Rowe Price Extended Equity Market Index Fund71,546US$334KJun 30, 2026
Fidelity Nasdaq Composite Index Fund61,523US$269KMay 31, 2026
Vanguard Institutional Total Stock Market Index Fund54,231US$253KJun 30, 2026
Small Cap Index Fund52,537US$245KJun 30, 2026
Vanguard Balanced Index Fund51,583US$241KJun 30, 2026
Fidelity ZERO Total Market Index Fund48,266US$168KJul 31, 2026
Global X Russell 2000 ETF48,213US$168KJul 31, 2026
U.S. Vector Equity Portfolio43,247US$150KJul 31, 2026
Schwab Total Stock Market Index Fund40,958US$143KJul 31, 2026
ATM Small Cap Managed Volatility Portfolio36,061US$168KJun 30, 2026
MetLife Russell 2000 Index Portfolio34,803US$163KJun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio34,200US$160KJun 30, 2026
Fidelity ZERO Extended Market Index Fund33,636US$117KJul 31, 2026
Small-Cap Index Portfolio28,962US$135KJun 30, 2026

This page holds 50 of 116 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Adams Kendra
Officer: Chief Financial Officer
Sale45,173USD 2.71US$122KNov 12, 2026

Big stakes

StakeStakeSharesDateFiling
Lynx1 Capital Management LP9.99%15.4MJun 30, 2026Schedule 13G
Soleus Capital Master Fund, L.P.9.99%10.4MDec 31, 2025Schedule 13G
Ra Capital Management, L.P.9.90%13.7MSep 30, 2026Schedule 13G
Sirenia Capital Management LP9.90%23.5MMar 31, 2026Schedule 13G
Squadron Capital Management LLC7.90%9.72MSep 30, 2026Schedule 13G
BlackRock, Inc.6.90%7.68MJun 30, 2026Schedule 13G
BCLS II Equity Opportunities, LP6.25%6.06MOct 17, 2025Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Owen Hughes
Other companies: AnaptysBio, Inc. (Director · Since at least May 11, 2026); XOMA Royalty Corporation (Chief Executive Officer, Director · Since at least Nov 11, 2024); ImageneBio, Inc. (Director · Dec 14, 2022 – Jun 7, 2024 · Past); Pardes Biosciences Inc (Director · Feb 16, 2021 – Dec 23, 2021 · Past); Cullinan Therapeutics, Inc. (President and CEO, Director · Jan 7, 2021 – Jan 12, 2021 · Past); Translate Bio Inc (Director · Jun 27, 2018 – Sep 14, 2021 · Past); Radius Health, Inc. (Director · Apr 23, 2013 – Aug 15, 2022 · Past)
Director · Since at least Nov 16, 2023
Adam Crystal
Other companies: Tango Therapeutics, Inc. (President, Research & Development · Since at least Feb 27, 2023)
Chief Medical Officer · May 25, 2022 – Jan 30, 2023 · Past
Donna Grogan
Other companies: Momenta Pharmaceuticals Inc (Director · Sep 18, 2019 – Oct 1, 2020 · Past)
Director · Since at least Jul 29, 2022
Jolie Siegel
Other companies: Odyssey Therapeutics, Inc. (See Remarks · Since at least May 7, 2026)
Chief Legal Officer · Oct 1, 2020 – Feb 13, 2025 · Past
Marc Cohen
Other companies: Korro Bio, Inc. (Director · Oct 2, 2019 – Jun 21, 2022 · Past)
In MemoriamCo-Founder & Executive Chairman Emeritus · Since at least Oct 1, 2020
Alain J CohenDirector · Oct 1, 2020 – Apr 4, 2022 · Past
Andrew HirschPresident and Chief Executive Officer, Director · Since at least Aug 11, 2026
Courtney SolbergAssociateDirector, Investor Relations · Since at least Nov 3, 2026
Ken AndersonDirector · Since at least Oct 2, 2026
Kendra AdamsChief Financial Officer · Since at least Sep 18, 2023
All 21 people
PersonSeat
Kenneth Carl AndersonDirector · Since at least Oct 1, 2020
Laura BessenDirector · Since at least Jun 18, 2025
Laura Jean WahlbergVP of Finance Corp Controller · Oct 1, 2020 – Feb 11, 2021 · Past
Leah GibsonVice President, Investor Relations & Communications · Since at least May 20, 2026
Leonard ReynoChief Medical Officer · Since at least Jul 10, 2023
Owen HughesDirector · Since at least Nov 5, 2026
Ron CooperChairman · Since at least Nov 4, 2026
Scott N BoyleChief Business Officer · Since at least Feb 13, 2026
Stephen FawellDirector · Since at least Aug 29, 2024
Steve HoerterDirector · Since at least Nov 20, 2024
Utpal KoppikarDirector · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about C4 Therapeutics, Inc.